Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

716
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
716
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.5K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peroxisomal catalase and plasmalogen biosynthesis protect from oxidative stress in Barth syndrome cardiomyopathy.

Basic research in cardiology·2026
Same author

Desmoglein-2 Deficiency Drives Mitochondrial Morphological Remodeling in Cardiomyocytes.

American journal of physiology. Heart and circulatory physiology·2026
Same author

Hierarchical endpoints and win statistics for geromedicine trials.

Nature aging·2026
Same author

Alterations in Cardiac and Systemic Metabolism in Heart Failure.

Circulation. Heart failure·2026
Same author

European funding for cardiovascular research: room for improvement for the ERC track.

European heart journal·2026
Same author

ERA4Health funded project: liver-heart crosstalk in heart failure.

European heart journal·2026
Same journal

The origin of clinical left ventricular ejection fraction measurement.

Nature reviews. Cardiology·2026
Same journal

Inclusive cardiovascular care for sexual and gender minority populations.

Nature reviews. Cardiology·2026
Same journal

Modular cardiac microtissues for interrogating cell-type contributions.

Nature reviews. Cardiology·2026
Same journal

Sleep and exercise can limit clonal haematopoiesis clone expansion and reduce associated atherosclerosis.

Nature reviews. Cardiology·2026
Same journal

Epigenetic regulation in atherosclerosis and its therapeutic potential.

Nature reviews. Cardiology·2026
Same journal

Coronary artery calcium on chest CT scans: from incidental finding to mandatory reporting.

Nature reviews. Cardiology·2026
See all related articles

Related Experiment Video

Updated: Sep 8, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

Mechano-energetic uncoupling in heart failure.

Dunja Aksentijevic1, Simon Sedej2,3,4, Jeremy Fauconnier5

  • 1William Harvey Research Institute, Bart's Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK. d.aksentijevic@qmul.ac.uk.

Nature Reviews. Cardiology
|June 21, 2025
PubMed
Summary
This summary is machine-generated.

Heart failure (HF) involves disturbed cardiac mechano-energetic coupling. Therapies targeting this uncoupling offer new hope for treating heart failure (HF) and improving patient outcomes.

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.5K
Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.3K

Related Experiment Videos

Last Updated: Sep 8, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.5K
Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.3K

Area of Science:

  • Cardiology
  • Mitochondrial Biology
  • Metabolic Disorders

Background:

  • Heart failure (HF) is a growing global health crisis, exacerbated by aging populations and rising obesity.
  • Metabolic disorders significantly alter HF pathophysiology, impacting cardiac energy metabolism and function.
  • Key features of HF include impaired excitation-contraction coupling, mitochondrial dysfunction, and oxidative stress.

Purpose of the Study:

  • To review the intricate relationship between cardiac mechanics and mitochondrial energetics in HF.
  • To elucidate how mechano-energetic coupling is disrupted in various forms of HF.
  • To explore therapeutic strategies targeting mechano-energetic uncoupling in HF.

Main Methods:

  • Literature review focusing on cardiac mechanics, mitochondrial function, and HF pathophysiology.
  • Analysis of mechano-energetic coupling disruptions in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF).
  • Examination of the role of oxidative stress and therapeutic interventions.

Main Results:

  • In HFrEF, impaired excitation-contraction coupling drives mechano-energetic uncoupling.
  • In HFpEF, increased mechanical workload from obesity and hypertension outpaces mitochondrial ATP supply.
  • Oxidative stress exacerbates cardiac remodeling and dysfunction in both HF types.

Conclusions:

  • Mechano-energetic uncoupling is a central mechanism in HF pathogenesis.
  • Targeting mechano-energetic coupling presents promising therapeutic avenues for HF.
  • Further understanding of these mechanisms can lead to novel treatments for HF.